GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The evolution of endocrine therapy for breast cancer (BC) accounts for more than 120 years (ovariectomy, use of testosterone, tamoxifen). in 1982, the use of gonadotropin-releasing hormone agonists (GnRH agonists) instead of ovariectomy in women with metastatic breast cancer and preserved menstrual function was first described. In 2017, it was proved (according to the combined analysis of SOFT/TEXT trials) that premenopausal patients with early hormone-positive BC with a persistent premenopausal estrogen levels after adjuvant chemotherapy (CT) and metastatic lesion of ≥4 lymph nodes and/or G3 malignancy degree, the addition of ovarian suppression to adjuvant hormone therapy reduces the risk of death, recurrence and contralateral BC compared with monotherapy with tamoxifen. For ovarian suppression, GnRH agonist triptorelin was used in in most patients in TEXT/SOFT trials. It should be emphasized that after completion of drug ovarian suppression in young women, the initial quality of life is restored, the menstrual cycle is normalized, and the symptoms of GnRH agonist-induced menopause disappear. Advantages of the use of GnRH agonists include not only restoration of fertility in young patients, but also an improvement of its indices, in contrast to patients who have not yet received GnRH agonists.

Full Text

Restricted Access

About the authors

T. Yu Semiglazova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikovy

Email: tsemiglazova@mail.ru
MD, Head of the DepartmenT., Leading Scientist at the Research Department of Innovative Methods of Therapeutic Oncology and Rehabilitation

I. V Berlev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikovy

E. A Ulrikh

N.N. Petrov National Medical Research Center of Oncology

V. V Semiglazov

N.N. Petrov National Medical Research Center of Oncology; First St. Petersburg State Medical University n.a. Acad. I.P. Pavlova

A. E Protasova

North-Western State Medical University n.a. I.I. Mechnikovy; St. Petersburg State University

N. A Brish

N.N. Petrov National Medical Research Center of Oncology

E. A Korobeynikova

N.N. Petrov National Medical Research Center of Oncology

Yu. V Alekseeva

N.N. Petrov National Medical Research Center of Oncology

L. V Filatova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikovy

A. I Semenova

N.N. Petrov National Medical Research Center of Oncology

D. Kh Latipova

N.N. Petrov National Medical Research Center of Oncology

G. M Teletaeva

N.N. Petrov National Medical Research Center of Oncology

E. V Tkachenko

N.N. Petrov National Medical Research Center of Oncology

V. V Klimenko

N.N. Petrov National Medical Research Center of Oncology

G. A Dashyan

N.N. Petrov National Medical Research Center of Oncology

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

R. M Paltuev

N.N. Petrov National Medical Research Center of Oncology

A. F Urmancheeva

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikovy

P. V Krivorotko

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikovy

V. F Semiglazov

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikovy

References

  1. Beatson G., Edin M. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment of illustrative cases. Lancet. 1896:104-7.
  2. Ulrich P Testosterone (hormone mâle) et son rôle possible dans le traitement de certains cancers du Sein, Unio. Internat. Contra Cancrum. 1939;4:377.
  3. Horwitz K., Wei L., Sedlacer S., d'Arville C.N. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog. Horm. Res. 1985;41:249-316.
  4. Klijn J.G.M., de Jong F.H. Treatment with luteinising hormone releasing hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet. 1982:1213-16.
  5. Покровский В.М., Коротько ГФ. Физиология человека. 2-е изд., перераб. и доп. М.: 2003. 656 с. [Pokrovskij V.M., Korot'ko G.F. Human physiology. 2nd ed. Moscow, 2003. 656 p. (In Russ.)].
  6. Стенина М.Б., Жукова Л.Г., Королева И.А., и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. Практические рекомендации RUSSCO. 2017;7:105-34.
  7. Семиглазов В.Ф., Палтуев Р.М., Манихас А.Г. и др. Клинические рекомендации РООМ по диагностике и лечению РМЖ. Санкт-Петербург, 2017
  8. Fornier M.N., Modi S., Panageas K.S., et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575- 79.
  9. Abusief M.E., Missmer S.A., Ginsburg E.S., et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791-98.
  10. Swain S., Land S.R., Ritter M., et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial Breast Cancer. Res. Treat. 2009;113:315-20.
  11. Hellemond I., Vriens I., Peer Р., et al. Ovarian function recovery during anastrozole in breast cancer patients with chemotherapy-induced ovarian function failure. J. Natl. Cancer Inst. 2017 Dec 1;109(12).
  12. de Pedro M., Otero B., Martin B. Fertility preservation and breast cancer: a review. Ecancermedicalscience. 2015;9:503.
  13. Kim S., Klemp J., Fabian C. Breast cancer and fertility preservation. Fertil. Steril. 2011;95(5):1535-43.
  14. Letourneau J.M., Smith J.F., Ebbel E.E., et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012;118(18):45 79-88.
  15. Del Mastro L,, Boni L., Michelotti A., et al. Effect of the gonadotropin releasing hormone analogue triptorelin on the occurence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269-76.
  16. Lambertini M., Ceppi M., Poggio F., et al. Ovarian suppression using luteinizing hormone releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a metaanalysis of randomized studies. Ann. Oncol. 2015;26(12):2408-19.
  17. Venturelli М., Guaitoli G., Omarini C., Moscetti L. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. Breast Cancer. 2018;10:39-49.
  18. Lambertini M. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine. 2016;14:1.
  19. Lambertini M. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. San Antonio Breast Cancer Symposium. 2017. Abstract GS4-01.
  20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
  21. Coates A., Winer E., Goldhirsch A., et al.; Panel Members. Tailoring therapies improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 2015;26:1533-46.
  22. Gradishar W., Anderson B., Balassanian R. NCCN guidelines Breast Cancer version 1.2016. J. Natl. Compr. Canc. Netw. 2015;13(12):1475-85.
  23. Senkus E., Kyriakides S., Ohno S., et al.; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015; 26 (Suppl. 5):v8-30.
  24. Burstein H.J., Lacchetti C., Anderson H. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J. Clin. Oncol. 2016; 34:1689-701.
  25. Francis PA., Regan M.M., Fleming G.F., et ai.; SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2015;372:436-46.
  26. Pagani О., Regan M.M., Walley B.A. et al; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2014;371:107-18.
  27. Regan M.M., Francis PA., Pagani O., et al. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J. Clin. Oncol. 2016;34:2221-31.
  28. Fleming G., Francis P.A., Läng I,, et al. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. SABCS. 2017. Abstract 844 GS4-03.
  29. Francis P on behalf of Pagani O., Regan M.M., Fleming G.F., et at. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. SABCS. 2014. Abstract 844 GS4-02.
  30. Ribi K., Luo W., Bernhard J., et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. Clin. Oncol. 2016; 34:1601-10.
  31. Hadji Р.,, Coleman R.E., Wilson C., et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J. Bone Oncol. 2017;7:1-12.
  32. Coleman R., Body J.J., Aapro M., et al.; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann. Oncol. 2014;25(Suppl. 3):124-37.
  33. Committee on Gynecologic Practice ACOG Tamoxifen and uterine cancer. Comm. Opin. 2014;601:1-4.
  34. Hernandez R.K., Serensen H.T.,, Pedersen L. Tamoxifen Treatment and Risk of Deep Venous Thrombosis and Pulmonary Embolism. Cancer. 2009; 115(19):4442-49.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies